Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 2/20 | 0.35 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | HTR1D | P28221 | 1/20 | 0.32 |
| ▸ | SLC8A1 | P32418 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1509783 | 0.91 | CYP2D6 (0.30) | CYP2D6OPRK1 | |
| SCHEMBL27228693 | 0.73 | MMP2 (0.44) | CA2 | |
| SCHEMBL4297055 | 0.73 | MMP2 (0.44) | CA2 | |
| SCHEMBL7262682 | 0.71 | KEAP1 (0.43) | — | |
| SCHEMBL6591968 | 0.67 | CA2 (0.44) | CA2SSTR4CYP2D6OPRK1 | |
| SCHEMBL8650317 | 0.64 | CA2 (0.49) | CA2SSTR4HTR1AHTR1D | |
| Acetic Acid SCHEMBL27984668 | 0.63 | CA2 (0.44) | CA2SSTR4CYP2D6OPRK1HTR1A | |
| SCHEMBL8650215 | 0.62 | CA2 (0.46) | CA2SSTR4HTR1AHTR1D | |
| SCHEMBL6591970 | 0.61 | CA2 (0.45) | CA2SSTR4HTR1AHTR1D | |
| SCHEMBL6464770 | 0.61 | CA2 (0.49) | CA2SSTR4HTR1AHTR1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7897721-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2011-03-01 | — | — | US | disclosed |
| US-7795378-B2 | Peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-09-14 | — | — | US | disclosed |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-7473760-B2 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2009-01-06 | — | — | US | disclosed |
| US-7176279-B2 | Cyclic peptide compositions and methods for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2007-02-13 | — | — | US | disclosed |
| EP-1667700-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | Palatin Technologies, Inc. (US) | 2006-06-14 | — | — | EP | disclosed |
| US-20060111281-A1 | Cyclic peptide compositions for treatment of sexual dysfunction | PALATIN TECHNOLOGIES, INC. (US) | 2006-05-25 | — | — | US | disclosed |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | PALATINE TECHNOLOGIES, INC. (US) | 2005-06-09 | — | — | US | disclosed |
| WO-2005014617-A2 | CYCLIC PEPTIDE COMPOSITIONS AND METHODS FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
| WO-2004005324-A2 | PEPTIDE COMPOSITION FOR TREATMENT OF SEXUAL DYSFUNCTION | PALATIN TECHNOLOGIES, INC. (US) | 2004-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060111281-A1 | Cyclic peptide compositions for treatment of sexual dysfunction | VIP, GNRHR, NPR1 | CA2 3558/4885SSTR4 107/4885CYP2D6 4277/4885 |
| US-20050124553-A1 | Peptide compositions for treatment of sexual dysfunction | RXFP1, EDNRB, EDNRA | CA2 2712/4885SSTR4 45/4885CYP2D6 3792/4885 |
| US-20100121027-A1 | Cyclic Peptide Compositions for Treatment of Sexual Dysfunction | VIP, GNRHR, NPR1 | CA2 3558/4885SSTR4 107/4885CYP2D6 4277/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.